London, UK – 29 September 2021: genedrive plc (LSE: GDR), the near-patient molecular diagnostics company, announces that it has conditionally raised total gross proceeds of approximately £1.1 million through the
New Genedrive® system readied for Antibiotic Induced Hearing Loss launch
genedrive plc (AIM: GDR), the near-patient molecular diagnostics company, provides an update on the development of its Genedrive® COV19-ID Kit, a rapid Point of Care (PoC) molecular test for SARS-CoV-2
Genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that the Genedrive® 96 SARS-CoV-2 Kit has been formally approved by the Indian Council of Medical Research (“ICMR”).
Excellent performance of Genedrive®HCV -ID Kit in large multi-centre study
Genedrive successful in PHE National Framework Agreement for Diagnostics Goods and Services
genedrive plc (LSE: GDR), the near-patient molecular diagnostics company, announces unaudited interim results for the six months to 31 December 2020.
Genedrive enters distribution agreement with Mountain Horse Solutions
New clinical guidance in the UK supports assay
Genedrive plc (AIM: GDR), the near-patient molecular diagnostics company, announces the first shipments to the United States of its Genedrive® 96 SARS-CoV-2 Kits.
Distribution agreement with Beckman Coulter Life Sciences for COVID-19 PCR testing
